@Article{,
AUTHOR = {Jack Barkin},
TITLE = {Management of symptomatic benign prostatic hyperplasia-today},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {15},
YEAR = {2008},
NUMBER = {6},
PAGES = {4353--4358},
URL = {http://www.techscience.com/CJU/v15n6/62234},
ISSN = {1488-5581},
ABSTRACT = {Symptomatic benign prostatic hyperplasia (BPH) is one of 
the commonest causes of men presenting with lower urinary 
tract symptoms (LUTS). We can fi nd this in 50% of men 
over the age of fi fty. If BPH is not treated, then one can 
expect that the disease will progress in a signifi cant number 
of individuals. What we need to do is try to predict, based on 
certain baseline parameters such as International Prostate 
Score (IPSS), prostate volume, prostate-specifi c antigen 
(PSA) and the degree of bother, those men to whom we should 
offer therapy. The other consideration is that combination 
therapy of a 5-alpha reductase inhibitor (5-ARI) and an alpha 
blocker, may provide the best results for the prevention of 
progression of the disease or ultimately, the need for surgery. 
The fi nal considerations are “if”, for “how long” and “for 
whom” should combination therapy be utilized.},
DOI = {}
}